X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Caspase-8 (1C12) Mouse mAb antibody

RRID:AB_2275120

Antibody ID

AB_2275120

Target Antigen

CASP8 human

Proper Citation

(Cell Signaling Technology Cat# 9746, RRID:AB_2275120)

Clonality

monoclonal antibody

Comments

Applications: W, IP. Consolidation on 11/2018: AB_10284832, AB_10694352, AB_2068482, AB_2275120.

Host Organism

mouse

Vendor

Cell Signaling Technology

Cat Num

9746

Publications that use this research resource

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

  • Kolluri KK
  • Elife
  • 2018 Jan 18

Literature context:


Abstract:

Malignant mesothelioma (MM) is poorly responsive to systemic cytotoxic chemotherapy and invariably fatal. Here we describe a screen of 94 drugs in 15 exome-sequenced MM lines and the discovery of a subset defined by loss of function of the nuclear deubiquitinase BRCA associated protein-1 (BAP1) that demonstrate heightened sensitivity to TRAIL (tumour necrosis factor-related apoptosis-inducing ligand). This association is observed across human early passage MM cultures, mouse xenografts and human tumour explants. We demonstrate that BAP1 deubiquitinase activity and its association with ASXL1 to form the Polycomb repressive deubiquitinase complex (PR-DUB) impacts TRAIL sensitivity implicating transcriptional modulation as an underlying mechanism. Death receptor agonists are well-tolerated anti-cancer agents demonstrating limited therapeutic benefit in trials without a targeting biomarker. We identify BAP1 loss-of-function mutations, which are frequent in MM, as a potential genomic stratification tool for TRAIL sensitivity with immediate and actionable therapeutic implications.

Funding information:
  • Cancer Research UK - A17341()
  • NINDS NIH HHS - R01NS043915(United States)
  • Wellcome - WT097452MA()
  • Wellcome Trust - 106555/Z/14/Z()
  • Wellcome Trust - WT107963AIA()